I secured Canadian rights to Lanoxin from GSK Canada and US rights to Urex from 3M, then grew Vatring to $18M in annualized revenue. I modernized Urex’s formulation after 3M stopped manufacturing, winning FDA approval through a 505(b)(2) filing.
At S2 Therapeutics, I acquired worldwide rights to Cycloset, led an $18M private equity raise, and financed its development through FDA approval. I also advised on Santarus’s US launch and clinical direction.
At Wohlfahrt Haus, I helped shape a dinner theater around Broadway musicals and a full-service restaurant, later taking full operating control. I secured more than $1.1M in COVID relief grants and executed the sale of the theater assets to Red Stag, LLC in 2025.

